[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-fibroids-leiomyoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-fibroids-leiomyoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641710","phase-2-fatima-trial-egcg-and-vitamin-d3-for-prevention-of-fibroid-recurrence-100641710",false,"NCT07647198","FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence","FATIMA Trial: EGCG and Vitamin D3 for Secondary Prevention of Uterine Fibroids","FATIMA","Inclusion criteria:\n\nInclusion Criteria (all inclusion criteria must have been met before randomization unless otherwise specified and exceptions to inclusion criteria may be made at the discretion of the Principal Investigator, provided they are justified and ensure no compromise to the study's scientific integrity or participant safety):\n\nInclusion Criteria:\n\n1. Has voluntarily signed and dated the informed consent form before initiation of any screening or study-specific procedures.\n2. Premenopausal females aged 18 years and older on the day of signing of the informed consent form.\n3. Has a diagnosis of uterine fibroids that is confirmed by a pelvic ultrasound (transvaginal and\u002For transabdominal) performed during the screening period.\n4. Has at least one or more of the following symptoms:\n\n   1. Moderate to heavy menses defined as PBAC score ≥ 120\n   2. Pelvic pain during menses measured on NRS ≥ 4 at baseline\n   3. Moderately severe fibroid-related symptoms (a score ³ 25 on the UF quality of life symptoms severity subscale).\n5. Has a negative urine pregnancy test at the Screening, Baseline, and interval clinic visits\n6. Agrees to not be pregnant for at least 12 months. Participants may use any form of non-hormonal contraception consistently during the screening period and the randomized treatment period. These may include Diaphragm, cervical cap, spermicides, male and female condoms, copper IUD and sponge. Each one will be explained in detail for the participants. However, the patient is not required to use contraception if she:\n\n   1. Has a sexual partner(s) who was vasectomized at least 6 months before the screening period.\n   2. Had a bilateral tubal occlusion (including ligation and blockage methods such as Essure™), at least 4 months prior to the first screening visit (patients with Essure™ must have prior confirmation of tubal occlusion by hysterosalpingogram).\n   3. Is not sexually active with men; periodic sexual relationship(s) with men requires the use of dual non-hormonal contraception as noted above; or\n   4. Practices total abstinence from sexual intercourse as her preferred lifestyle; periodic abstinence is not acceptable.\n7. Has an endometrial (aspiration) biopsy, if clinically indicated, performed during the screening period, with results showing no clinically significant endometrial pathology (hyperplasia, endometritis, or endometrial cancer).\n\nExclusion Criteria:\n\n1. Participants with documented vitamin D deficiency (based on previous serum vitamin D level within prior 12 months).\n2. Has transvaginal and\u002For transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the patient's heavy menstrual bleeding, such as uterine or cervical polyps \\> 2.0 cm, or any other clinically significant gynecological disorder determined by the investigator to require further evaluation and\u002For treatment.\n3. Has unexplained vaginal bleeding outside of the patient's regular menstrual cycle.\n4. Has undergone ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance-guided focused ultrasound for fibroids, as well as endometrial ablation for abnormal uterine bleeding within 6 months prior to the screening visit.\n5. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face, and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the patient's bone mineral density is within normal limits.\n6. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss\n7. Anticipated use of systemic glucocorticoids at an oral prednisone-equivalent dose of more than 5 mg every other day during the study. Note: topical, inhaled, intranasal, optic, ophthalmic, intraarticular, or intralesional subcutaneous are permitted without restriction.\n8. Gastrointestinal disorder affecting absorption or gastrointestinal motility\n9. Has jaundice or known current active liver disease from any cause, including hepatitis A (HAV IgM), hepatitis B (HBsAg), or hepatitis C (HCV Ab positive, confirmed by HCV RNA).\n10. Has any of the following cervical pathology: high-grade cervical neoplasia, atypical glandular cells, atypical endocervical cells, atypical squamous cells favoring high grade. Of note, patients with atypical squamous cells of undetermined significance and low-grade cervical neoplasia may be included in the study if high-risk human papillomavirus testing is negative or if DNA testing for human papillomavirus 16 and 18 DNA testing is negative\n11. Has any history of clinical laboratory abnormalities indicating hepatic or gallbladder impairment.\n12. Has been a participant in an investigational drug or device study within the 1 month prior to the screening visit.\n13. Has a history of clinically significant condition(s) including, but not limited to:\n\n    1. Untreated thyroid dysfunction or palpable thyroid abnormality (patients with adequately treated hypothyroidism who are stable on medication are not excluded).\n    2. History of malignancy within the past 5 years or ongoing malignancy other than curatively treated nonmelanoma skin cancer or surgically cured Stage 0 in situ melanoma.\n14. Any current psychiatric disorder that would, in the opinion of the investigator or medical monitor, impair the ability of the patient to participate in the study or would impair the interpretation of their data. Patients with major depression, post-traumatic stress disorder, bipolar disorder, schizophrenia, or other psychotic disorders, based on Diagnostic and Statistical Manual of Mental Disorders-5 criteria who have been unstable based on the investigator's or mental health professional's judgement or whose psychiatric drug regimen has changed during the 3 months prior to Screening or is expected to change during the study should not be enrolled. Has a contraindication or history of sensitivity to any of the study treatments or components thereof; or has a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates study participation.\n15. Has a prior (within 1 year of Screening 1 visit) or current history of drug or alcohol abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders V (all patients must be questioned about their drug and alcohol use, and this should be documented in the electronic case report form).\n16. Has participated in a previous clinical study that included the use of Green tea or Vitamin D3 or has received this treatment within 3 months of the study.\n17. Is inappropriate for participation in this study for other reasons, as determined by the investigator, sub-investigator, or medical monitor.","FEMALE","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of this randomized controlled clinical trial is to evaluate the efficacy of green tea (EGCG) and vitamin D3 supplementation in preventing uterine fibroid recurrence following fibroid removal.",[27],"Uterine Fibroids (Leiomyoma)",[29,30,31,32],"Uterine fibroids","EGCG","Vitamin D3","Myomectomy","RECRUITING","2026-06-13",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":21},"2026-08-22",{"date":41,"type":21},"2029-12-22",{"name":43,"class":44},"Sheikh Shakhbout Medical City","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100629908","teas-combined-with-triple-antiemetic-drugs-to-prevent-ponv-in-high-risk-patients-100629908","NCT07480785","TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","Transcutaneous Electrical Acupoint Stimulation Combined With Triple Antiemetic Drugs for Postoperative Nausea and Vomiting in High-Risk Patients: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women scheduled for laparoscopic surgery ；\n* Aged 18-65 years；\n* ASA Class I-III；\n* Apfel score ≥ 3 (female sex, non-smoker, history of PONV and\u002For motion sickness).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to the investigational drug or contraindications；\n* Long-QT syndrome ；\n* Pregnancy, lactation, or menstruation ；\n* Current smoker；\n* Nausea\u002Fvomiting or use of antiemetics, opioids, or systemic corticosteroids within 24 h before surgery；\n* Requirement for post-operative sedation and mechanical ventilation ；\n* Severe renal or hepatic impairment ；\n* Psychiatric or neurological disorder ；\n* Vertebrobasilar insufficiency；\n* Vestibular disease；\n* Language or communication barrier ；\n* Skin lesion or infection at the acupoint stimulation site ；\n* Upper-limb nerve injury ；\n* Implanted cardiac pacemaker or defibrillator ；\n* Participation in another clinical trial within the past 4 weeks.","65 Years",{"count":55,"type":21},780,[57],"NA","The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.\n\nThe primary question it seeks to answer is:\n\nDoes TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.",[27,60,61],"Ovarian Tumors","Gallstones",[63,64,65],"postoperative nausea and vomiting","transcutaneous electrical acupoint stimulation","high-risk patients with PONV","2026-03-15",{"date":68,"type":37},"2026-03-18",{"date":70,"type":37},"2026-01-16",{"date":72,"type":21},"2027-10-31",{"name":74,"class":44},"Zhejiang University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100620064","bilateral-uterine-artery-occlusion-during-laparoscopic-myomectomy-100620064","NCT07352761","Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy","Comparing Different Techniques of Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* women with uterine fibroids and complaining of either abnormal uterine bleeding, infertility, urinary or rectosigmoid pressure manifestations.\n* Fibroid size from 3 - 10 cm in diameter and with\n* a maximum number of 3 fibroids.\n\nExclusion Criteria:\n\n* contraindication to pneumoperitoneum and laparoscopy,\n* patients with BMI \\> 30 kg\u002Fm2,\n* history of midline abdominal incisions,\n* women with history of prior ovarian surgery,\n* women with history of hormonal treatment for the last 3 months before surgery,\n* women who are not good candidate for myomectomy and who would benefit more from hysterectomy such as, women with multiple ≥ 4 leiomyomata, associated adenomyosis, recurrent fibroids after myomectomy.\n* suspected endometrial malignancy or suspected leiomyosarcoma features on ultrasound and\u002For MRI.\n* Submucous fibroids who will undergo hysteroscopic myomectomy beside the laparoscopic surgery.",{"count":83,"type":21},60,[57],"The current study is a multiple-arm, single blinded, and controlled randomized trial. It will be conducted in two gynecological endoscopy centers: • ElShatby University Hospital, a tertiary level hospital in Alexandria, Egypt. • Al-Madina Women Hospital, A specialized hospital of Obstetrics and Gynecology, Alexandria, Egypt. Patient selection: women with uterine leiomyomata and planning for laparoscopic myomectomy will be assessed for eligibility then will be enrolled in the trial according to the following inclusion and exclusion criteria, after providing a written informed consent of participation. Outcome variables of the study: The primary outcome is intraoperative blood loss and the change in postoperative hemoglobin. The secondary outcomes of this study are the operative time of performing uterine arteries occlusion and the postoperative ovarian reserve.",[27,32,87],"Myomectomy; Surgical Blood Loss",[89,90,91,92,93],"Fibroids","Laparoscopic myomectomy","Blood loss","Uterine artery occlusion","Ovarian reserve","2026-01-13",{"date":96,"type":37},"2026-01-20",{"date":98,"type":37},"2025-05-01",{"date":100,"type":21},"2026-02-28",{"name":102,"class":44},"Alexandria University",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":45},"100611069","efficacy-of-ultrasound-guided-microwave-ablation-in-the-treatment-of-uterine-fibroids-100611069","NCT07235787","Efficacy of Ultrasound Guided Microwave Ablation in the Treatment of Uterine Fibroids.","MWAUF","Inclusion Criteria:\n\nFemale patients aged 25 years or older Good general health Symptomatic uterine fibroids suitable for microwave ablation as determined by examining gynecologist Premenopausal status Acceptable risks for general anesthesia or sedation Number of fibroids: fewer than 5 Size of fibroid: less than 10 cm\n\nExclusion Criteria:\n\nOngoing anticoagulant treatment and\u002For known bleeding disorder Chronic diseases contraindicating general anesthesia Pregnancy Postmenopausal status 5 or more fibroids Fibroid size 10 cm or larger Poor general health precluding anesthesia or sedation","25 Years",{"count":113,"type":21},20,[57],"Uterine fibroids are the most common benign tumors of the female genital tract and can significantly affect the quality of life in reproductive-age women, causing symptoms such as heavy menstrual bleeding, pelvic pressure, urinary disturbances, dyspareunia, and infertility. Traditional surgical interventions such as myomectomy and hysterectomy remain the standard of care, yet they are associated with considerable trauma, longer recovery times, and the loss of uterine function.\n\nMicrowave ablation (MWA) is a minimally invasive image-guided technique that uses microwave energy to induce coagulative necrosis in fibroid tissue, reducing its size and alleviating symptoms while preserving the uterus. This study aims to evaluate the feasibility, safety, and therapeutic effectiveness of ultrasound-guided percutaneous microwave thermal ablation (PMTA) in the management of symptomatic uterine fibroids.\n\nEligible participants are premenopausal women aged 25 years or older with symptomatic fibroids less than 10 cm in size and fewer than five in number. Exclusion criteria include pregnancy, bleeding disorders, chronic diseases contraindicating anesthesia, and ongoing anticoagulant therapy.\n\nEach participant will undergo ultrasound-guided microwave ablation under aseptic conditions and sedation. Fibroid size, menstrual bleeding patterns, hemoglobin levels, and pain scores will be evaluated at baseline and during follow-up at 3 and 6 months. The primary outcome is the reduction in fibroid size, while secondary outcomes include symptom improvement and hemoglobin level changes.\n\nThis prospective case series will be conducted at Assiut University Hospitals, Egypt, with 20 participants referred from the Gynecology Department to the Interventional Radiology Unit. The results will provide valuable data on the clinical value of MWA as a uterus-preserving alternative for symptomatic uterine fibroids.",[27,117],"Symptomatic Uterine Leiomyoma",[29,119,120,121],"Leiomyoma","Microwave ablation (MWA)","Ultrasound-guided ablation","NOT_YET_RECRUITING","2025-11-16",{"date":125,"type":37},"2025-11-19",{"date":127,"type":21},"2025-11-30",{"date":129,"type":21},"2027-12-01",{"name":131,"class":44},"Jihad Hussien Mohamed Mahmoud"]